Bangi APRIL 3, 2018 – CCM Duopharma Biotech Berhad (Duopharma) expects its newly completed Effervescent plant in Bangi, the country’s first ever such facility, to put the Company at the forefront of technology development in manufacturing high-quality pharmaceutical products using Effervescent technology that offers advantages over conventional manufacturing of healthcare products.

The RM7 million Effervescent plant, which was commissioned in October 2017, has the capability to produce 107 million tablets of Flavettes Effervescent Vitamin C annually. Through the latest investment, Duopharma expects to roll out various effervescent products under the company’s current range of award winning OTC brands, such as Flavettes, Champs, Proviton and Uphamol. This range of effervescent products will provide consumers with a choice of a new delivery format for health supplements, which is seen to be a preferred trend in the market.

In November 2017, Duopharma launched 4 new effervescent products under the Flavettes brand, and this range of Vitamin C products has been well accepted by the market, with an overwhelming demand. Speaking at a media familiarisation trip to the Effervescent plant, Leonard Ariff Abdul Shatar, Group Managing Director of CCM Duopharma Biotech Berhad, said that Duopharma’s latest production facility is part of the Company’s Manufacturing Optimisation Strategy (MOS) which includes rationalising and upgrading its facilities to accelerate growth.

“There is a great demand for Effervescent pharmaceutical products, especially Flavettes Effervescent Vitamin C, in the market as they offer many functional benefits to consumers including providing a much easier way to ingest supplements instead of having to swallow a tablet, and giving a pleasant taste compared to regular tablets.

“As a leading pharmaceutical company in Malaysia, Duopharma strives to be at the vanguard of new technology as we constantly explore ways to enhance our customer experience. Formulating and manufacturing Effervescent products requires specialised knowledge and technological skill with an excellent environmental infrastructure to control the temperature and humidity of the production facility to ensure optimal product stability,” said Leonard Ariff. Effervescent technology enables tablets to dissolve into a solution once they are in contact with water. This allows active ingredients to dissolve completely and evenly as well as to absorb quicker into the bloodstream compared to conventional formulations, resulting in faster onset of action.

Flavettes Effervescent Vitamin C provides customers who lead a hectic lifestyle with an efficient and convenient means of getting their daily health requirements to help them stay refreshed and healthy throughout their busy schedule. It consists of a three-in-one formulation of Glutathione, Vitamin C and E which helps ward off free radicals to keep skin stay healthy, youthful and beautiful.

“We operate in a highly competitive and fast-moving industry. Hence, we acknowledge the great need to invest and embrace new technologies in order to stay ahead of the competition. We are proud to be the first pharmaceutical company in Malaysia to bring Effervescent technology to the local market and we are confident that our plant’s cutting-edge equipment and expertise will significantly contribute to our goal of becoming one of the top five generic
pharmaceutical companies in Southeast Asia by 2022,” he added. Duopharma is currently the largest Good Manufacturing Practice (GMP) – Pharmaceutical certified manufacturer in Malaysia with facilities in Bangi, Klang and Glenmarie. This standard ensures all production activities in every plant are in line with the standards established by Malaysia’s Health Ministry’s GMP and international standards. Duopharma was the first pharmaceutical company to be presented with the distinguished ‘Halal Malaysia’ certification for prescriptive medicine issued by the Malaysian Islamic
Development Department (JAKIM) based on the world’s first Halal pharmaceutical standard, MS2424:2012. The Company’s GMP and Halal-compliant facilities ensure that its pharmaceutical products are carefully prepared, manufactured, packaged and stored in a clean and secured condition as it continues to deliver a best-in-class customer experience. The Company recorded a revenue of RM468 million for the financial year ended 2017, an increase of 49.5 per cent as compared to the same period the previous year.